Glaucoma is a progressive eye disease that can lead to irreversible vision loss if left untreated. Current treatment options for glaucoma focus on reducing intraocular pressure (IOP) to slow down the progression of the disease. However, there is still a need for more effective therapies that can provide long-term benefits for patients.
PER-001 intravitreal implant offers a novel approach to treating glaucoma by targeting ischemia-induced ocular diseases. The implant delivers therapeutic agents directly into the vitreous humor, bypassing traditional systemic delivery routes and allowing for higher drug concentrations at the site of action.
The Phase 1/2a clinical trial aims to evaluate the safety, tolerability, and efficacy of PER-001 intravitreal